DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,971,050 | +6.9% | 144,916 | +3.4% | 0.39% | -1.8% |
| Q2 2023 | $33,645,634 | -3.8% | 140,123 | +1.0% | 0.40% | -16.6% |
| Q1 2023 | $34,972,498 | -2.4% | 138,777 | +2.8% | 0.48% | -5.2% |
| Q4 2022 | $35,837,068 | +16.9% | 134,977 | +13.8% | 0.50% | +12.1% |
| Q3 2022 | $30,653,000 | -25.6% | 118,560 | -27.0% | 0.45% | +8.7% |
| Q2 2022 | $41,210,000 | -17.6% | 162,442 | -4.8% | 0.41% | +0.5% |
| Q1 2022 | $50,036,000 | -6.9% | 170,582 | +4.4% | 0.41% | +0.7% |
| Q4 2021 | $53,755,000 | +8.2% | 163,361 | 0.0% | 0.41% | -2.9% |
| Q3 2021 | $49,703,000 | +204.6% | 163,361 | +168.6% | 0.42% | +224.8% |
| Q2 2021 | $16,317,000 | +19.2% | 60,809 | 0.0% | 0.13% | +9.3% |
| Q1 2021 | $13,694,000 | +1.3% | 60,809 | 0.0% | 0.12% | -4.1% |
| Q4 2020 | $13,512,000 | +14.1% | 60,809 | +10.5% | 0.12% | +7.9% |
| Q3 2020 | $11,842,000 | +28.0% | 55,009 | +5.1% | 0.11% | +17.5% |
| Q2 2020 | $9,254,000 | +69.2% | 52,358 | -25.4% | 0.10% | +15.5% |
| Q4 2016 | $5,468,000 | – | 70,200 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |